London, UK, 26 February 2013: MRC Technology, a technology transfer charity and company, today reported successful results from the first year of its agreement with the Association for International Cancer Research (AICR). The partnership enables AICR to take advantage of MRC Technology’s IP management, technology transfer, and drug discovery expertise, to help maximise the health benefits and revenue derived from AICR-funded research.
Over the year, MRC Technology’s experts reviewed and monitored 25 priority projects from AICR’s overall portfolio, advising on development and commercialisation as appropriate.
For three of these projects, MRC Technology negotiated revenue share agreements on behalf of AICR with the universities holding the grants. Each of these agreements reflects the value of the support given by AICR towards the success and commercialisation of the research.
Mike Johnson, MRC Technology’s Director of Corporate Partnerships commented: “The success of this relationship is based on the ability of MRC Technology to add value to AICR’s mission, ensuring that research funded by the organisation creates potential new health benefits wherever possible. We look forward to continuing our work with AICR, and to building similar partnerships with other charities and universities.”
Dr Helen Rippon, Head of Science at AICR commented, “We very much value our partnership with MRC Technology, and recognise their expertise in managing and commercialising IP. We are a small team at AICR, and only through our partnership with MRC Technology can we ensure that opportunities are not missed for AICR-funded research to be steered towards patient benefit. We have found their open, honest and regular communication and flexibility to be of great benefit through the past year. We look forward to continuing the relationship and further realising returns on AICR-funded research for people affected by cancer”